Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common drug shield kidneys from protein damage?

NCT ID NCT02343094

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether sodium phenylbutyrate, a drug already used for other conditions, can reduce a marker of kidney injury in people with proteinuric kidney disease. 26 participants took the drug for 14 days. The goal was to see a 50% drop in a urine marker called Lcn2, which signals kidney stress.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sodium phenylbutyrate
What this could lead to
If it works, this could point toward a new treatment to protect kidneys in people with proteinuric kidney disease.
What could go wrong
This is a small, early-phase trial with only 26 participants. It measures a lab marker, not long-term kidney health, so success is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

26 people

The number who actually took part.

Start date

Feb 2015

Finished

Jul 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chronic Kidney disease for ore than 3 months * Proteinuria \> 1g/d or 0,1g/mmmol creatinine * eGFR \>30ml/mn/1,73m2 * written informed consent * affiliated with social security health insurance Exclusion Criteria: * Women with childbearing potential * Recent (\<3 months) modification of ACE inhibitors or ARB * Acute renal failure * eGFR \<30ml/mn/1,73m2 * Nephrotic syndrome (albuminélia \<30g/l) * Infection with HIV, HCV, HBV * Liver insufficiency * No affiliated with social security health insurance * inclusion in another protocol of biomedical research * risk of non-adherence to protocol and visits * patients having a cardiac insufficiency of grade 3 or 4 * patient requiring of a strict salt-free diet * patients under corticoids or immunosuppresseurs * clinical intolerance in the treatment * intolerance in the fructose, the syndrome of malabsorption glucose and galactose or a deficit in sucrase / isomaltase * patients treated by Probenecide

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Proteinuric diseases

Contacts and locations

Locations

  • Hôpital Necker Enfants Malades

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.